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Background: Glaucoma is an optic neuropathy that is characterized by the loss of retinal ganglion cells (RGCs)
initiated by damage to axons in the optic nerve. The degeneration and death of RGCs has been thought to occur
in two waves. The first is axogenic, caused by direct insult to the axon. The second is somatic, and is thought to be
caused by the production of inflammatory cytokines from the activated retinal innate immune cells. One of the
cytokines consistently linked to glaucoma and RGC damage has been TNFα. Despite strong evidence implicating
this protein in neurodegeneration, a direct injection of TNFα does not mimic the rapid loss of RGCs observed
after acute optic nerve trauma or exposure to excitotoxins. This suggests that our understanding of TNFα signaling
is incomplete.
Methods: RGC death was induced by optic nerve crush in mice. The role of TNFα in this process was examined by
quantitative PCR of Tnfα gene expression, and quantification of cell loss in Tnfα−/− mice or in wild-type animals
receiving an intraocular injection of exongenous TNFα either before or after crush. Signaling pathways downstream
of TNFα were examined by immunolabeling for JUN protein accumulation or activation of EGFP expression in NFκB
reporter mice.
Results: Optic nerve crush caused a modest increase in Tnfα gene expression, with kinetics similar to the activation
of both macroglia and microglia. A pre-injection of TNFα attenuated ganglion cell loss after crush, while ganglion
cell loss was more severe in Tnfα−/− mice. Conversely, over the long term, a single exposure to TNFα induced
extrinsic apoptosis in RGCs. Müller cells responded to exogenous TNFα by accumulating JUN and activating NFκB.
Conclusion: Early after optic nerve crush, TNFα appears to have a protective role for RGCs, which may be mediated
through Müller cells.
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Optic neuropathies, of which glaucoma is the most com-
mon, are characterized by axonal degeneration in the
optic nerve and apoptotic death of retinal ganglion cell
(RGC) somas, leading to irreversible vision loss [1-3].
While the exact mechanisms that initiate RGC injury
have not been clearly established, animal models of ele-
vated intraocular pressure, axotomy, and optic nerve
crush mimic the apoptotic pathways observed during* Correspondence: nickells@wisc.edu
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unless otherwise stated.glaucomatous neurodegeneration [4-9]. Although direct
axonal injury ultimately leads to RGC somatic death,
resident innate immune cells have long been suspected
of playing a critical role during glaucoma [10-15]. Den-
dritic cells have been shown to infiltrate the damaged
retina after crush injury [16]; however, it is the retinal
glial cells, specifically macroglia (astrocytes and Müller
cells) and microglia that comprise the principal popula-
tions of resident immune cells in the retina. Under nor-
mal circumstances these cells maintain retinal health,
but after an injury they undergo an activation response
to behave as innate immune cells by presenting antigens
and releasing cytokines and other small molecules intoal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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repair and remove critically injured neurons [15,20]; how-
ever, the effect of prolonged glial activation on RGC sur-
vival continues to be debated. Some research suggests that
the innate immune response is critical for RGC protection
after injury [21,22], while research in stroke and ischemia
models demonstrate greater neuronal loss from activated
glia [14,23,24]. More specifically in the latter paradigm,
glial activation is thought to cause a second wave of RGC
loss, termed secondary degeneration [7,11,25].
The model of secondary degeneration proposes that
ganglion cell death during glaucoma occurs in two waves:
first, that axonal injury culminates in the death of a subset
of RGCs and the activation of retinal glia; and second, that
the activated glia then produce cytotoxic molecules, such
as inflammatory cytokines, that critically damage surviving
RGCs [7,11,25-27]. It has been hypothesized that these cy-
tokines are generated from either macroglia, principally
Müller cells [28], or microglia [20], or both. Supporting
evidence for this model comes from studies showing that
minocycline, a broad spectrum anti-inflammatory drug,
protects RGCs against optic nerve axotomy, experimental
glaucoma, and optic nerve crush [7,29-31], implicating a
damaging role for the immune response after injury. While
many inflammatory cytokines have been linked to RGC de-
generation [21,32,33], TNFα has been consistently associ-
ated with glaucomatous neuropathy [10,11,23,34-37].
TNFα is a pro-inflammatory cytokine that is elevated in
several neurological diseases including multiple sclerosis
[33], Alzheimer’s disease [38] and ischemia [24]. It is gen-
erated in the retinas of human glaucoma patients [35] as
well as animal models of retinal injury [11,23,28,36,39-42].
Additionally, the receptors through which TNFα signals,
TNFα receptor 1 (TNFR1) and TNFα receptor 2 (TNFR2),
are also upregulated after retinal injury [35,43,44]. Isolat-
ing TNFα from the complex degenerative signaling path-
ways activated by RGC injury has yielded conflicting
results about the role of this cytokine in RGC damage.
TNFα is thought to contribute to RGC pathology follow-
ing NMDA injection and optic nerve crush, which re-
spectively cause RGC death within hours to days [5,7,45];
yet an intraocular injection of TNFα requires 2 weeks to
cause axonal injury and 8 weeks before RGC somatic loss
is significant [10,36,46]. Although TNFα injection does ul-
timately result in RGC loss, the disconnect in the timing
of RGC damage suggests that TNFα may not simply flip a
switch initiating degeneration, but may instead trigger a
cascade of signaling networks that indirectly culminate in
neuronal damage over time.
A possible explanation for this disconnect may be the
opposing roles for TNFR1 and TNFR2 [43,47,48]. In
human glaucoma, TNFR1 has been linked with the up-
regulation of pro-apoptotic proteins including BAX and
CASP1 [37], and TNFR1 deficiency protected neuronalcell cultures from glutamate excitotoxicity [47], and in-
creased RGC survival in a mouse model of optic nerve
crush [11,37]. Conversely, TNFR2 deficiency increased
neuronal susceptibility to glutamate [47], and caused
greater RGC loss in a mouse model of ischemia/reperfu-
sion [43]. Given that TNFα appears to play an important
role during retinal injury, there is a clear need to better
understand through which pathway(s) this cytokine is
signaling. The present study investigates further the role
of TNFα in the pathology of RGCs after optic nerve
damage in mice. After optic nerve crush we detected a
modest increase in Tnfα gene expression. Experimental
evidence suggests that this inflammatory cytokine may
have a protective role early in the RGC death process.Materials and methods
Animals
Adult C57BL/6J mice (Jackson Laboratory, Bar Harbor,
ME, USA) were handled in accordance with the Associ-
ation for Research in Vision and Ophthalmology statement
on the use of animals in research. All experimental proto-
cols and the ethical care of the mice were reviewed and
approved by the Institutional Animal Care and Use
Committee of the University of Wisconsin. Mice were
housed in microisolator cages and kept on a 12-hour
light/dark cycle and maintained on a 4% fat diet
(8604 M/R; Harland Teklad, Madison, WI, USA). Bax-
deficient mice were generated from breeding Bax+/−
animals on a C57BL/6J background. Tnfα−/− mice were
obtained from the Jackson Laboratory and as a gift from
Dr Matyas Sandor at the Univeristy of Wisconsin. NFκB
expression was monitored with cis-NFκBEGFP reporter
mice [49] that were obtained from Dr Christian Jobin at
the University of North Carolina. All genotypes were on
the C57BL/6J background.Optic nerve crush surgery
Prior to surgery, mice were anesthetized with ketamine
(120 mg/kg) and xylazine (11.3 mg/kg) and the eye
numbed with a drop of 0.5% proparacaine hydrochloride
(Akorn, Lake Forest, IL, USA). Optic nerve crush surgery
was performed as previously described [5,9]. Briefly, a lat-
eral canthotomy was performed followed by an incision
through the conjunctiva at the limbal junction. The sclera
was cleared of excess tissue before the optic nerve was ex-
posed using self-closing N7 forceps (Fine Science Tools,
Foster City, CA, USA), and clamped for 3 seconds. After
surgery, the eye was covered with triple antibiotic oint-
ment, and a subcutaneous injection of buprenex (0.2 mg/
kg) was delivered to alleviate pain. Surgery was not per-
formed on the right eye of each mouse, as previous studies
have shown that mock surgery does not affect ganglion
cell morphology or number [50,51].
Table 1 Quantitative PCR primer sequences
Gene name Primer sequence 5’→ 3’ Size (bp)
Aif1 Forward: AGAGAGGTGTCCAGTGGC 200
Reverse: CCCCACCGTGTGACCTCC
Gfap Forward: CAAACTGGCTGATGTCTACC 269
Reverse: AGAACTGGATCTCCTCATCC
Nrn1 Forward: TTCACTGATCCTCGCGGTGC 238
Reverse: TACTTTCGCCCCTTCCTGGC
Sncg Forward: GACCAAGCAGGGAGTAACGG 240
Reverse: TCCAAGTCCTCCTTGCGCAC
Tnfα Forward: CGCGACGTGGAACTGGCAGAA 276
Reverse: GTGGTTTGCTACGACGTGGGCT
S16 Forward: CACTGCAAACGGGGAAATGG 198
Reverse: TGAGATGGACTGTCGGATGG
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Mice were anesthetized with ketamine/xylazine and a
drop of proparacaine was applied to numb the eye. A
small hole was made through the conjunctiva and scleral
tissue with a 30G needle, and then a 30G beveled Nanofil
needle attached to a Nanofil syringe (World Precision In-
struments, Inc., Sarasota, FL, USA) was inserted through
the hole and a 2 μl volume of either 50 ng or 100 ng
TNFα (Sigma, St Louis, MO, USA) was slowly delivered
to the vitreous over 60 seconds. Care was taken not to
damage the lens. After delivery, the needle was held in the
eye for an additional 30 seconds before being retracted. A
subcutaneous injection of buprenex was delivered to alle-
viate pain and the mouse was allowed to recover.
RNA isolation and quantitative analysis of mRNA
expression by quantitative PCR
Mice were euthanized with a lethal overdose of pento-
barbital sodium prior to tissue harvest. Retinal tissue
was collected and flash frozen on dry ice. At least three
retinas were analyzed for each condition tested. Total
RNA was isolated from the tissue using a solution of
50% phenol containing 1.67 M guanidine thiocyanate,
14.3 mM sodium acetate, 10.4 mM sodium citrate, 0.3%
β-mercaptoethanol, and 0.005% Sarkosyl. Retinal tissue
was sonicated in 1 ml of the phenol solution with 10
pulses at 50% power using a Branson Sonifier SLPe En-
ergy Cell Disruptor (All-Spec Industries, Willmington,
NC, USA). The RNA was then extracted with chloroform
and precipitated with isopropanol. The pellet was washed
in 70% ethanol and dried before being resuspended in
DEPC-treated water (Fisher Scientific, Waltham, MA,
USA). The total RNA concentration was determined using
a BioPhotometer (Eppendorf, Hamburg, Germany). A
DNase treatment with DNase I (Promega, Madison, WI,
USA) was then performed on 4 μg of RNA to eliminate
contaminating genomic DNA. The DNase-treated RNA
samples were extracted with phenol and chloroform, and
precipitated with ethanol. The pellet was washed with
70% ethanol and dried before being resuspended in
DEPC-treated water (Fisher Scientific). Finally the RNA
was converted to cDNA with oligo(dT) 15 primers and
Moloney murine leukemia virus reverse transcriptase
(Promega).
The cDNA samples were then diluted and 100 ng was
analyzed by quantitative PCR (qPCR) for changes in
gene expression of Aif1, Gfap, Nrn1, Sncg, Tnfα and S16
ribosomal protein mRNA. The cDNA was added to di-
luted SYBR Green PCR master mix (Applied Biosystems,
Grand Island, NY, USA) with 0.25 μM of each primer in
a 20 μl reaction volume. Each cDNA sample was run in
triplicate on an ABI 7300 Real Time PCR system (Applied
Biosystems), superimposed on a standard curve to deter-
mine absolute transcript quantities, and normalized toS16. Cycling conditions were 95°C (15 seconds) and 60°C
(60 seconds) for 40 cycles with a dissociation step. Primer
sequences are listed in Table 1.Cell counts from retinal whole mounts
After euthanasia the superior portion of the eye was
marked with a cautery, and then the whole eye was
enucleated and fixed in 4% paraformaldehyde. After
50 minutes, the eye was rinsed in PBS and the anterior
segment removed to create an eye cup. The retina was
removed from the eye cup and placed with the ganglion
cell layer (GCL) facing up onto a Superfrost Plus slide
(Fisher Scientific); three additional relaxing cuts were
made to allow the retina to lay flat. The whole mounts
were stained with 300 ng/ml 4’,6-diamidino-2-phenylin-
dole (DAPI; Fisher Scientific) and then thoroughly
rinsed in PBS before being covered with Immu-mount
(Fisher Scientific), coverslipped and stored at 4°C in the
dark. Images were captured at 400× from all around the
periphery of the retina, and nuclear counts were ob-
tained from 24 distinct fields (120 μm2) for each retina
and averaged together. Only rounded nuclei with at
least one nucleolus, typical of both RGCs and amacrine
cells in this layer, were included in the counts. Endothe-
lial cells exhibiting elongated nuclei and no nucleolus,
and densely staining astrocytes were excluded [52]. The
GCL cell counts for each experimental retina were com-
pared to the cell counts for the corresponding contralat-
eral retina using the following formula to yield a percent
change: [(cell count experimental) – (cell count control)]/
(cell count control) × 100. Retinal ganglion cells represent
about 50% of the GCL population [53]. It should be noted
that while Bax−/− mice have twice as many neurons as
wild-type mice, the RGCs still represent about 50% of the
GCL population [54].
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Whole eyes were fixed in 4% paraformaldehyde before
the anterior segment was removed to create an eye cup.
The eye cups were then rinsed in PBS, post-fixed over-
night in 0.4% paraformaldehyde, and equilibrated in 30%
sucrose in PBS. The eye cups were embedded in optimal
cutting temperature compound (Fisher Scientific) in blocks
and frozen on dry ice. Frozen sections were cut at 10 to
14 μm. Slides were rinsed in PBS and then blocked in 0.2%
Triton-X, 1% BSA, and 5% donkey serum in PBS for 1 hour
at room temperature. Primary antibodies (see Table 2) were
incubated overnight at 4°C in PBS containing 1% BSA.
Slides were thoroughly rinsed in PBS and incubated in
Texas Red-conjugated or FITC-conjugated secondary anti-
bodies (Jackson ImmunoResearch, Inc., West Grove, PA,
USA) in the dark for 2 hours at room temperature in PBS
containing 1% BSA. Slides were thoroughly rinsed in PBS
before being incubated with 300 ng/ml DAPI for 5 minutes
at room temperature. Finally, the slides were rinsed in PBS
and coverslipped with Immu-Mount and stored at 4°C in
the dark.
Whole mounts labeled with BRN3A were stained as
previously described by Nadal-Nicolas and colleagues
[55], with minor modifications. Briefly, following fixation
of the globe, the anterior segment was removed and the
eye cups were incubated in PBS containing 0.5% Triton-
X100 and 2% donkey serum (Jackson ImmunoResearch,
Inc.) for 1.5 hours at room temperature. They were then
transferred into the same buffer containing primary anti-
body (see Table 2) overnight at 4°C. After incubation,
the eye cups were thoroughly rinsed in PBS with 0.5%
Triton-X100, and then fixed for an additional 10 minutes
in 4% paraformaldehyde. Eye cups were rinsed in PBS
and whole mounted onto Fisher Plus slides, and then
incubated in 2% Triton-X100 and 2% donkey serum with
1:500 secondary antibody (Jackson ImmunoResearch)
for 2 hours at room temperature. The whole mounts
were rinsed in PBS and stained with 300 ng/ml DAPI for
5 minutes at room temperature. After a final wash with
PBS, the slides were coverslipped with Immu-Mount
and photographed.Table 2 Primary antibodies
Protein name Acronym Species
Allograft inflammatory factor 1 AIF1 Polyclonal ra
BRN3A BRN3A Monoclonal
Caspase 3 CASP3 Polyclonal ra
Glial fibrillary acidic protein GFAP Polyclonal ra
JUN JUN Polyclonal ra
Transcription factor SOX-9 SOX9 Polyclonal ra
Tumor necrosis factor alpha TNFα Polyclonal g
aRichmond, VA, USA; bBillerica, MA, USA; cMinneapolis, MN, USA; dCarpinteria, CA, UMicroscopy
All immunofluorescent photographs were acquired using
a Zeiss Axioplan 2 Imaging microscope (Carl Zeiss Micro-
imaging, Inc., Thornwood, NY, USA) with a digital black
and white camera. Images were analyzed using the Zeiss
Axiovision Image Analysis software v4.6 (Carl Zeiss
Microimaging, Inc.).
Statistical analyses
Means from qPCR quantification are reported with the
standard deviation of the mean, and cell counts are re-
ported with standard error. Statistical significance between
two means was determined using a two-sided Student’s
t-test. P values were considered significant at a value equal
to or less than 0.05.
Results
TNFα expression is stimulated following optic nerve crush
injury
An increase in Tnfα mRNA expression has been corre-
lated with RGC and optic nerve injury; however, the
time course of this expression to the best of our know-
ledge has not been documented. Therefore, the changes
in Tnfα mRNA were analyzed by qPCR at 1, 3, 5, 7, and
14 days after optic nerve crush. Absolute mRNA levels
in the retina were low across all time points in the injured
retina. By 3 days after optic nerve injury, TNFα expression
was significantly elevated in the injured retina compared
to the contralateral eye, and remained significantly higher
at 5 and 7 days after injury (Figure 1A; P <0.05). Fourteen
days after injury, the difference in TNFα mRNA levels was
no longer significant (Figure 1A; P =0.94). This pattern of
expression mirrored the increase in markers for glial acti-
vation, specifically Aif1 expression in microglia and Gfap
expression in macroglia (Figure 1B). Conversely, tran-
scripts of two genes selectively expressed in RGCs were
downregulated during this time frame (P <0.05 for all
genes and time points, crush relative to contralateral naïve
eyes, Figure 1C), consistent with previous observations
indicative of RGC damage from crush injury [56-59].
Western blots and enzyme-linked immunosorbent assayDilution Company Catalog #
bbit 1:1000 WAKOa 019-19741
mouse 1:50 Milliporeb MAB1585
bbit 1:1000 R&Dc AF835
bbit 1:1000 DAKOd Z0334
bbit 1:1000 Abcame Ab40766
bbit 1:1000 Millipore AB5535
oat 1:100 R&D AF-410-NA
SA; eCambridge, MA, USA.
Figure 1 Retinal Tnfα mRNA expression increases after optic
nerve crush. (A) Tnfα gene expression was monitored by quantitative
PCR at 1, 3, 5, 7 and 14 days after optic nerve crush. Within 1 day of
optic nerve crush, the level of TNFα expression began to increase
compared to contralateral naïve eyes. At 3, 5, and 7 days after crush,
TNFα expression was significantly elevated (P <0.05). By 14 days after
injury, a time when about half of retinal ganglion cells have died
from crush injury, TNFα levels were no longer statistically significant
(P = 0.94). (B) The rise in Tnfα mRNA correlated with the increase in
mRNA accumulation of glial activation markers Aif1 (microglia) and
Gfap (macroglia). Expression peaked for both markers between 5 and
7 days before declining at 14 days. The increase in expression in the
injured retina was significant for all genes at all time points (P <0.01,
relative to the contralateral eye). (C) Retinal ganglion cell gene
markers, Nrn1 and Sncg, declined within 1 day of optic nerve crush
and remained low, consistent with RGC injury following optic nerve
damage (P <0.05, relative to the contralateral eye). Data are
presented as mean ± SE; n ≥3 for all timepoints.
Mac Nair et al. Journal of Neuroinflammation 2014, 11:194 Page 5 of 14
http://www.jneuroinflammation.com/content/11/1/194data did not reveal a quantifiable change in TNFα pro-
tein (data not shown).
TNFα mediates retinal ganglion cell death through
extrinsic apoptosis
An intraocular injection of TNFα induces RGC death
and optic nerve degeneration [10,36,46], indicating that
these cells are responsive to the toxic effects of this cyto-
kine. Some discrepancies exist, however, in the mode of
action by TNFα. First, toxicity to the RGC somas only
manifests after several months from the initial exposure
[36,46], making it unclear how TNFα participates in path-
ologies like N-methyl-D-aspartate injection and optic
nerve damage, which lead to RGC death more rapidly [5].
Second, RGC death induced by axonal damage is abso-
lutely dependent on the intrinsic apoptotic pathway, since
these cells are completely refractory to this insult when
lacking the pro-apoptotic Bax gene [54,60,61]. Conversely,
the predicted mode of action for TNFα is through the
extrinsic pathway, independent of BAX activation [15].
To test which apoptotic pathway is essential for TNFα-
induced RGC death, wild-type and Bax−/− mice were
given an intraocular injection of TNFα and then assayed
for cell loss at 6 and 8 weeks after injection.
Consistent with other studies, injected TNFα induced
cell loss, but only after 8 weeks (Figure 2A). The total
number of cells in wild-type mice significantly declined
8 weeks after treatment with 10 ng and 100 ng TNFα
(8.97% and 19.41%, respectively; P <0.005, compared to
PBS-injected eyes). Similarly, Bax-deficient RGCs were
also susceptible to 10 ng and 100 ng TNFα, with the total
number of RGC layer neurons declining by 8.11% and
15.03% (P <0.001, compared to PBS-injected eyes). PBS in-
jections alone did not cause significant cell loss (wild types
P =0.36, knockouts P =0.40, relative to contralateral eye).
The effect of exogenous TNFα was not limited to a
small percentage of RGCs, however. In similar experi-
ments we stained retinal whole mounts for the RGC
marker BRN3A, which can be depleted in damaged RGCs
well in advance of cell death [56,62]. At 8 weeks after in-
jection of 100 ng TNFα, there was undetectable BRN3A
staining in retinas of both wild-type and Bax−/− mice ex-
posed to this cytokine (Figure 2B-E). Thus, even though
there is only a loss of 30 to 40% of the RGCs (after correc-
tion of the percentage of RGCs that make up the total
number of neurons in the ganglion cell layer [53]), ex-
ogenous TNFα appears to cause some level of damage to
the entire population of these cells.
TNFα deficiency exacerbates retinal ganglion cell injury
after optic nerve crush
To determine if TNFα contributes to RGC pathology after
optic nerve crush, we performed surgery on Tnfα−/− mice
and obtained cell counts after 7, 14, and 21 days
Figure 2 TNFα mediates extrinsic apoptosis of retinal ganglion
cells in a dose-dependent manner. (A) A single intraocular
injection of TNFα was delivered and the total number of cells in
the ganglion cell layer (GCL) was obtained from 4’,6-diamidino-2-
phenylindole-stained retinal whole mounts after 8 weeks. No cell
loss was detected at 6 weeks (data not shown). Wild-type (black
bars) and Bax−/− mice (gray bars) exhibited dose-dependent loss of
total cells, indicating cell death occurred via a Bax-independent
mechanism. The percent change was calculated by comparing the
injected eye to the control eye. Statistics were calculated relative to
the PBS-injected control group and are presented as mean ± SE
(*P <0.005, **P <0.001); n ≥3 for all genotypes and conditions.
(B-E) Retinal whole mounts were also stained for the retinal ganglion
cell-specific transcription factor BRN3A. Approximately 40% of the
neurons in the GCL stain for BRN3A in control retinas of both wild-type
(B) and Bax−/− (D) mice [53,55]. Retinas exposed to a single injection of
TNFα, 8 weeks prior, exhibit a complete absence of BRN3A staining
(wild-type mice in C, and Bax-deficient mice in E). Scale bar =15 μm.
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been shown to confer significant resistance to acute optic
nerve damage in mice [11], we observed greater cell loss
in the Tnfα-deficient mice compared to the wild types.
Although RGC loss was not significantly different 7 days
after injury between the wild type and Tnfα−/− mice
(8.84% compared to 7.15% total cell loss, respectively;
P =0.50), by 14 days Tnfα−/− mice had lost 19.46% of the
total cells, while the wild-type mice only showed an
11.61% decline in their total RGC layer neurons (P <0.001).
Cell loss continued to decline in both genotypes 21 days
after crush, but there was again significantly greater loss in
Tnfα−/− mice relative to the wild types (26.55% compared
to 20.32%, respectively; P <0.001). In complimentary exper-
iments, we also quantified the level of Caspase 3 (CASP3)
activation after optic nerve crush in Tnfα−/− mice. Previous
studies have documented that CASP3 activity peaks be-
tween 3 and 5 days in this experimental paradigm [50,63].
Consistent with the cell count data, Tnfα−/− mice exhibited
significantly more CASP3 activity by 3 days after optic
nerve crush compared to wild-type mice (P <0.05), al-
though by 5 days the percent of CASP3+ cells was not
statistically different (Figure 3B,C).A single injection of TNFα protects retinal ganglion cells
when delivered prior to optic nerve crush
Dissecting out a single cytokine from a complex map of
signaling pathways by genetic deletion is likely an over-
simplification of any disease pathology. It is more
plausible that TNFα is part of a larger orchestrated in-
jury response, and without auxiliary injury signals this
cytokine may be limited in its effectiveness. We there-
fore tested the effect of TNFα when delivered in con-
junction with injury to RGCs by optic nerve crush. We
tested two conditions: first, the cytokine was delivered
prior to optic nerve crush to pre-activate the TNFα sig-
naling network, which is expectedly enhanced following
crush injury.
When an intraocular injection of 100 ng TNFα was
delivered 5 days prior to crush injury, RGC loss was re-
duced by almost 50% 1 week after crush, compared to
PBS-injected crushed mice (Figure 4A, P <0.001). This
protective effect persisted, relative to PBS-injected eyes,
to 14 days post-crush, although cell density decreased in
both cohorts of mice (P <0.001). A second condition
was also tested in which 100 ng TNFα was delivered
7 days after optic nerve crush; however, there was no
statistically significant difference in cell survival be-
tween any of the groups subjected to crush (Figure 4B,
P >0.05). These results support our findings above that
TNFα may protect RGCs from optic nerve injury and,
importantly, will not exacerbate damage when applied
after the initial insult to the optic nerve.
Figure 3 Mice deficient for Tnfα have greater retinal ganglion cell loss from crush than wild-type mice. (A) Wild-type and Tnfα−/− mice
were subjected to optic nerve crush and analyzed for total retinal ganglion cell layer neuronal cells remaining at 7, 14, and 21 days after injury.
The decline in cell numbers was not statistically significant between the two genotypes at 7 days, but at 14 and 21 days Tnfα−/− mice had
significantly more cell loss (*P <0.001 for both time points). (B,C) Retinal whole mounts from wild-type and Tnfα−/− mice were analyzed for
Caspase 3 (CASP3) activation 3 and 5 days after optic nerve crush. At 3 days, Tnfα−/− mice has a significantly greater number of CASP3+ cells
(*P <0.05), but by 5 days the difference between the two genotypes was no longer significant. Results are presented at mean ± SE (A,C); n ≥3 for
all genotypes. Scale bar (B) =50 μm. GCL, ganglion cell layer.
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monitoring
The data shown in Figures 3 and 4 illustrate a positive
role for TNFα after RGC injury; however, the mechanisms
of protection are still unclear. Others have reported that
TNFα can act in an autocrine manner to augment the glial
response after an injury, particularly in the astrocytes and
microglia [64-67], which may help protect neurons from
subsequent damage [48,68]. Therefore, in the absence of
TNFα, the retinal glia may inadequately respond to an
injury and render neurons more susceptible to degener-
ation. We next tested whether TNFα was critical for glialFigure 4 Pre-treatment with TNFα improves retinal ganglion cell surv
TNFα either (A) 5 days prior to optic nerve injury (pre-treatment) for neuro
(post-treatment) and analyzed for cell counts 7 days later (14 days after cru
crush-induced cell loss by 50% 7 days after crush (P <0.001). Although cell
crush, the protection afforded by pre-treating with TNFα continued to be s
survival after crush (P >0.05). A single injection of TNFα alone yielded no si
relative to contralateral eye). Data are presented as mean ± SE; n ≥3. GCL, gactivation by comparing the microglial and macroglial ac-
tivation responses after optic nerve crush in wild-type and
Tnfα−/− mice.
The absence of TNFα minimally affected glial activation,
as a function of Aif1 and Gfap expression; wild-type and
Tnfα−/− mice showed almost identical activation trends.
Microglial activation (Aif1) peaked in the injured retinas
7 days after crush (301% in wild-type mice, 366% in
Tnfα−/− mice, P <0.001 relative to contralateral eye) and
then declined at 14 and 21 days to 66.6% and 41.9%,
respectively (Figure 5A, P <0.05). The increase in Aif1
expression was also detectable by immunofluorescenceival after crush. Mice were treated with an intraocular injection of
nal cell counts 7 and 14 days after crush, or (B) 7 days after crush
sh injury). Pre-treatment with TNFα (A) reduced the amount of
loss continued to decline in both cohorts between 7 and 14 days after
ignificant (P <0.001). Post-treatment (B) with TNFα did not affect RGC
gnificant cell loss after (A) 12 days, or (B) 7 days (P >0.05, injected eye
anglion cell layer.
Figure 5 TNFα is not required for glial activation as a function of Aif1 or Gfap expression. (A,B) Wild-type and Tnfα−/− mice were subjected
to crush, and expression levels for activation markers of microglia (Aif1) and microglia (Gfap) were assessed by quantitative PCR. Wild-type and
knockout mice followed similar glial activation trends for both markers. Micoglial activation (A) peaked in the injured retina 7 days after crush in
both wild-type and Tnfα−/− mice. Macroglial activation (B) was also significantly elevated in the injured retina by 7 days in both genotypes, with
peak expression occurring between 7 and 14 days. (C,D) Immunolabeling revealed a similar increase in allograft inflammatory factor (AIF)1 (red)
and glial fibrillary acid protein (GFAP; green) protein 7 days after crush injury. AIF1-positive cells were prominent in the ganglion cell layer (GCL)
and inner and outer plexiform layers. GFAP processes labeled through the retinal layers, consistent with Müller cell activation. Tnfα deficiency did
not affect baseline levels of Aif1 or Gfap. Overall, there was no discernible difference in the expression patterns of AIF1 or GFAP between the
wild-type and Tnfα-deficient mice either before or after injury. Sections were counterstained with 4’,6-diamidino-2-phenylindole (blue). Data are
presented as mean ± SD; *P <0.001, **P <0.01; n ≥3 for each genotype at each time point. Scale bar (C,D) =50 μm. INL, inner nuclear layer; ONL,
outer nuclear layer.
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http://www.jneuroinflammation.com/content/11/1/194labeling in retinal sections, with positive cells manifesting
in the inner and outer plexiform layers as well as the gan-
glion cell layer (Figure 5C). Macroglial activation (Gfap) in
wild-type and Tnfα−/− mice also trended similarly, with
expression rising by 7 days to 305.6% and 277.0% in the
wild types and Tnfα-deficient mice, respectively (Figure 5B,
P <0.001 relative to contralateral eye). Gfap mRNA levels
remained steadily elevated at 14 days after crush (301.7%
in wild types, 299.9% in Tnfα−/− mice), before considerably
declining at 21 days to 139.2% and 91.56% (P <0.001 rela-
tive to contralateral eye). Glial fibrillary acid protein
underwent a distinct morphological change with processes
labeling through the retinal layers, consistent with Müller
cell activation [20,30], and in the ganglion cell layer
where astrocytes reside (Figure 5D). Overall, there wasno significant distinction between microglial or macro-
glial activation in the wild-type and Tnfα−/− mice.
TNFα activates NFκB and causes JUN accumulation in
Müller cells
Although TNFα does not appear to be required for glial
activation as a function of Aif1 or Gfap expression, it
may be a critical extracellular signal that initiates pro-
tective networks within the activated glia after a retinal
injury. Two known targets of TNFα signaling are the tran-
scription factors NFκB [40,47] and JUN [69], and these two
proteins have been shown to work cooperatively to regu-
late gene transcription [70-73]. The activation of NFκB has
been correlated with resistance to ligand-mediated apop-
tosis [74,75], and JUN has been linked with both protective
Figure 6 An intraocular injection of TNFα activates NFκB in
Müller cells. cis-NFκBEGFP reporter mice underwent optic nerve
crush and were analyzed for enhanced green fluorescent protein
(EGFP) expression as an indicator of NFκB activation. EGFP was not
detected in control eyes (A), nor was it detected at 1, 3, 5, 7, or
14 days after crush injury (B); thus optic nerve injury and the
resultant RGC death does not cause retinal NFκB activation. In
contrast to this, while an intravitreal injection of PBS did not activate
NFκB in the retina (C), there was robust activation of NFκB as early
as 1 day after an intravitreal injection of 100 ng TNFα (D). EGFP
(green) was present through the retina from the ganglion cell
layer (GCL) to the outer limiting membrane, consistent with NFκB
activation in Müller cells. (E-G) NFκB activity (EGFP expression)
co-labeled with the Müller cell marker SOX9 (red, asterisk). NFκB was
not expressed in cells absent for SOX9; however, some SOX9+ cells
did not show activated NFκB (arrow). Sections were counterstained
with 4’,6-diamidino-2-phenylindole (blue). Scale bars (D) =50 μm
and (G) =10 μm; n ≥3 for each treatment at each time point. INL,
inner nuclear layer; ONL, outer nuclear layer.
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http://www.jneuroinflammation.com/content/11/1/194and apoptotic pathways in injured RGCs [51]. It is possible
that TNFα is mediating protection through one or both of
these transcription factors, so we next explored the effect
of TNFα on NFκB activation and JUN accumulation.
Using cis-NFκBEGFP reporter mice [49], in which en-
hanced green fluorescent protein (EGFP) is transcribed by
activated NFκB, we first examined whether optic nerve in-
jury activated NFκB in the retina. We expected to find
that NFκB activation would correlate with the time course
of TNFα expression observed after crush; however, retinal
sections did not reveal a detectable increase in NFκB ac-
tivity following optic nerve crush (Figure 6B). We next
tested the effect of an intraocular injection of TNFα into
one eye of the reporter mice. Unlike crush, exogenous
TNFα caused a clear activation of NFκB as early as 1 day
after treatment (Figure 6D), and remained prevalent by
3 days before returning to baseline levels at 5 days (data
not shown). The activity of NFκB was independent of the
injection procedure, as eyes injected with PBS did not
show any evidence of EGFP expression (Figure 6C). NFκB
activation by TNFα co-localized with SOX9, which select-
ively labels Müller cells [76]. Interestingly, only a subset of
Müller cells appeared to exhibit NFκB activation.
Optic nerve crush has previously been shown to cause
nuclear accumulation of JUN in RGCs [50,51]. Similar
to NFκB activation, however, an intraocular injection of
TNFα caused a significant increase in JUN nuclear accu-
mulation in the inner nuclear layer, and to a lesser extent
in the GCL (Figure 7F). This accumulation occurred as
early as 7 hours after TNFα exposure, and co-localized
with SOX2, a marker for Müller glia and amacrine cells
[77,78]. A morphologically distinct population of SOX2-
positive cells in the GCL also showed an accumulation of
JUN, which could be displaced amacrine cells or astro-
cytes (Figure 7F, arrows). While TNFα caused JUN accu-
mulation in the majority of the Müller cell population,
only a subset of the JUN-positive cells also exhibited
NFκB activation.
Discussion
The role of TNFα in neurodegeneration has been exten-
sively studied, yet caveats still remain in understanding the
mechanism by which it contributes to disease. In the con-
text of RGC injury and death, TNFα has been considered
by some researchers as detrimental and has been modeled
as a secondary inducer of RGC loss [7,11,13,25-27,79]. In
accordance with the literature supporting this theory, we
found that Tnfα mRNA is elevated in our model of optic
nerve crush, and that the cytokine does lead to a delayed
loss of RGCs through an extrinsic apoptotic mechanism.
However, a single intraocular injection of TNFα does not
cause rapid RGC loss as is seen with other ocular injury
models to which TNFα has been linked. Additional re-
search supports that TNFα is beneficial and protective toneurons [43,47,48,80]. Consistent with this we found that
genetic deletion of the Tnfα gene rendered mice more sus-
ceptible to optic nerve injury, and that pre-treatment with
exogenous TNFα promoted RGC survival after crush. It
appears contradictory that TNFα is both detrimental and
protective to RGCs; however, our data present a poten-
tially critical timing component that has not previously
been studied in regards to TNFα signaling in the retina.
More specifically, it appears that early TNFα exposure
prior to an injury may be protective, while chronic TNFα
Figure 7 An intraocular injection of TNFα causes nuclear accumulation of JUN in Müller cells. (A-C) PBS injections revealed a baseline
accumulation of JUN in the ganglion cell layer (GCL) with minimal activation in the inner nuclear layer (INL). (D-F) A single injection of TNFα
resulted in widespread accumulation of JUN (red) in SOX2-positive Müller cells (green) as early as 7 hours after treatment. A subset of SOX2-
positive cells were negative for JUN and exhibited rounded nuclei and no processes that may be amacrine cells (F, arrows). Additionally, in the
GCL a subset of SOX2+ cells also exhibited JUN nuclear accumulation and may be astrocytes. (G-I) Most of the Müller cells responded to TNFα
with an increase in labeling for JUN accumulation, but only a subset of these also upregulated NFκB (arrow). Cells were counterstained with
4’,6-diamidino-2-phenylindole (blue, I). After injection, sections were analyzed at 7 hours (n =3; A-F), and 24 hours (n =3; G-I). Scale bars
(F) =50 μm and (I) =10 μm.
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http://www.jneuroinflammation.com/content/11/1/194expression may eventually culminate in neuronal damage
and loss.
This phenomenon of neuronal protection from pre-
conditioning has been previously observed in stroke
patients, in which those with a history of transient ische-
mia attacks fared better following a cerebral infarction
than those without a similar history [81]. This protection
has been mimicked in cell culture models of neuronal
insult and animal models of brain ischemia with TNFα
exposure prior to a damaging stimulus [47,82]. Early
treatment with TNFα has been positively correlated with
survival pathways mediated by a number of proteins, in-
cluding phosphoinositide-3-kinase [47], the transcription
factor NFκB, and the histone acetyltransferase CREB bind-
ing protein [82]. The upregulation of CREB binding pro-
tein was observed only in neurons, even when co-cultured
with astrocytes [82], suggesting that TNFα was acting dir-
ectly on the neurons and not being mediated through the
glia. However, in the retina, astrocytes are only one sub-
population of glial cells - Müller cells and microglia also
contribute to retinal health and injury repair, complicat-
ing the mechanism by which TNFα may be promoting
RGC survival.
TNFα signals through TNFR1 and TNFR2, and follow-
ing retinal ischemia and a mouse model of glaucoma,
both receptors are upregulated in cells of the inner nu-
clear layer and GCL [43,44]. TNFR1 is a transmembrane
protein with an intracellular death domain that, upon
activation, can interact with adaptor proteins and initiate
apoptosis through CASP8 [37,83,84], and several studieshave shown that Tnfr1−/− mice exhibit significantly less
RGC loss than wild-type mice after injury [11,43]. In
comparison, TNFR2 does not contain a death domain
and has been linked with sustained NFκB activation
[43,47]. Unlike the RGC protection seen after injury with
Tnfr1 deficiency, Tnfr2−/− mice fair worse than wild-type
mice following ischemia [43] and glutamate excitotoxi-
city [47]. Interestingly, the Tnfα−/− mice in our study
more closely reflect the enhanced RGC pathology seen
in Tnfr2−/− mice after injury. This might suggest a pref-
erence for TNFα to bind TNFR2, possibly explaining the
protection afforded when TNFR1 is genetically ablated,
restricting TNFα to signal through the TNFR2 protective
networks. Alternatively, Tnfr2 deficiency may enhance
apoptotic signals through TNFR1, rendering central ner-
vous system tissue more susceptible to injury. In both
scenarios, it seems critical to understand the proteins
downstream of each receptor that are being affected
after injury, and in particular which retinal cell types are
responding to this cytokine.
It is important to note that while we have shown an
early protective potential of TNFα, the long-term conse-
quence of TNFα exposure still appears to be detrimen-
tal. This dual function of TNFα may reflect different
responses of individual cell types to this cytokine, which
is consistent with a recent publication by Dvoriantchikova
and Ivanov [85]. Their research found that, in response to
TNFα, RGC cultures exhibited sustained JNK activation
and death, while astrocytes upregulated NFκB and pro-
moted survival [85]. Therefore, the localization of TNFα
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influence whether TNFα has a beneficial or detrimental
effect on RGCs. TNFα is expressed by a number of innate
immune responders, and has been co-localized to optic
nerve head, nerve fiber layer, GCL, and the inner nuclear
layer of human glaucoma patients [34,35,43,86], and is up-
regulated by macroglia and microglia in the optic nerve
and optic nerve head [11,34]. Additional studies have
shown that dendritic cells also infiltrate the retina follow-
ing a similar optic nerve crush paradigm described here
[16,87], and it is conceivable that they may be the source
of TNFα. The proximity of TNFα production to specific
cell types in the retina may generate the differential pro-
tective versus detrimental effects. The protective effects
may occur through an indirect mechanism, by TNFα-
induced changes in retinal glia. Based on the rapid
induction of NFκB activity and JUN accumulation after
exposure to exogenous TNFα, we attribute this rapid re-
sponse to Müller cells (see below). Conversely, the detri-
mental effects may result from a direct interaction with
the RGCs. Kitaoka and colleagues noted that intravitreal
injection of TNFα in rabbits resulted in relatively early-
onset axonal damage followed by soma death many weeks
after TNFα exposure [40].
Unlike the delayed effect of TNFα on RGC somas, we
have shown that Müller cells respond rapidly to TNFα
within 1 day of exposure by accumulating JUN and upreg-
ulating NFκB, two known targets downstream of TNFα
[85]. It is important to note that JUN is activated by phos-
phorylation; however, the p-JUN antibody is less reliable
than that for JUN due to cross-reactivity [50]. Therefore,
the data presented in this manuscript are documented as
nuclear accumulation of JUN rather than activation. Add-
itionally, JUN is known to autoregulate its own expression
following its activation [88], and JUN levels have been
used as a surrogate of JUN activity. In response to an in-
traocular delivery of TNFα, both JUN and NFκB exhibit
nuclear activity, and it is interesting that the primary glial
cells responding to TNFα are the Müller cells. However,
while JUN accumulation was present in all of the Müller
cells, only a subset exhibited NFκB activity. This might
suggest that JUN is upstream of NFκB, and that all of the
Müller cells have not yet been able to activate the latter
gene, although the literature suggests a more complex
interplay between these transcription factors [71,73]. It is
also unclear if either of these pathways are involved in the
protective effect of TNFα. However, given the strong asso-
ciation of NFκB with survival pathways [47,73], it is pos-
sible that the cells expressing this transcription factor
might be mediating the protective effect seen in our stud-
ies involving intravitreal injection of exogenous TNFα. A
paradox with this interpretation, however, is that neither
JUN nor NFκB were activated after optic nerve crush.
While this may have been a function of reduced or morelocalized levels of TNFα production (such as by infil-
trating dendritic cells), it remains unclear how the
endogenous TNFα signaling response provides a pro-
tective environment for RGCs. Further studies involving
cell-specific ablation of one or both of these transcrip-
tion factors are needed to decipher whether they play a
role in the endogenous TNFα protective effect.
The signaling pathways activated in the injured retina
are complex, but we have identified a critical timing
component in TNFα signaling: specifically, that early ex-
posure to this cytokine protects RGCs from subsequent
optic nerve damage. A considerable amount of literature
has identified a damaging role for TNFα, yet this research
has indirectly focused on the effect of TNFα signaling late
after injury. Future studies should consider the advantage
of early immune activation in the retina, specifically with
an emphasis on Müller cell activation. By bolstering pro-
tective pathways early, rather than eliminating cytokine
signaling entirely, RGC loss may be minimized following a
severe insult and improve the prognosis for patients with
optic neuropathies, such as glaucoma.
Conclusion
Our studies underscore that while long-term exposure
to TNFα is toxic to RGCs, this cytokine appears to initi-
ate protective pathways that improve RGC survival im-
mediately following optic nerve injury. The mechanism
of protection may be occurring through TNFα activation
of Müller cells.
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